Clinical trial · Expanded Access
UARK 2009-32 Compassionate Use Study of Carfilzomib
Compassionate Use Study of Carfilzomib for Patients With Relapsing or Resistant Multiple Myeloma
NCT00999414CI-TRIAL-000195712009-32no longer availableClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a compassionate use, open-label, IND study for the purpose of providing carfilzomib to patients with relapsed or resistant refractory multiple myeloma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Carfilzomib | Drug | Carfilzomib | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Participants must have histologically documented multiple myeloma which is relapsing or resistant after stem cell transplantation, or when other conventional therapies have failed or are contraindicated * Serum creatinine \< 3.0 mg/dL OR calculated creatinine clearance \>15 mL/min calculated or measured clearance is ≥15 mL/min * ANC \> 1000/mm3 (may be supported with growth factors) * Platelet count \> 30,000/mm3 (may receive transfusion) * Female participant of child-bearing potential has agreed to use dual methods of contraception for the duration of the study * Male participant has agreed to use a barrier method of contraception if sexually active with a female of child-bearing potential * Patients must have signed and IRB-approved written informed consent form and demonstrate willingness to meet follow-up schedule and study procedure obligations Exclusion Criteria: * Active infection requiring systemic treatment * Requires concomitant use of approved or investigative anticancer therapeutic treatment with activity against multiple myeloma, other than dexamethasone * Concomitant use of other investigative agents (e.g., antibiotics or antiemetics) * Pregnant or breast-feeding
References
Publications (0)
Data not yet available
No reference posted for this study.